Stock Research

Use this section to find out about a particular company or look up a term in our glossary.

GSK - GlaxoSmithKline

GSK
1,736.50
14.92 (+0.87%)
ASK PRICE BID PRICE CHANGE
1,736.50 1,736.00 14.92 (+0.87%)
Volume 4,508,512
Day's high 1,738.00
Day's low 1,317.50
Today’s open 1,715.50
Prev Close 1,721.50
   

Index: FTSE 100, FTSE 250, FTSE All-Share & techMARK

Sector: Pharmaceuticals & Biotechnology

  • Company URL: http://www.gsk.com
  • Company Profile: GlaxoSmithKline Plc is a healthcare conglomerate. The current company formation is the result of a merger between drug companies GlaxoWellcome and SmithKline Beecham in 2000. GSK's principal pharmaceutical products include medicines or vaccines to treat conditions including asthma, cancer, mental health, diabetes, viruses and digestive problems. Glaxo's consumer health and nutrition divisions owns such brands as Aquafresh toothpast, Panadol tablets, NiQuitin and Nicorette nicotine treatments, and Lucozade and Ribena soft drinks.

GSK Graph

Chart: 1m   3m   6m   Advanced Charting

Set GSK Alert

GSK Trade Tendency

BullBearings trader activity in the last few days with this stock

Buying: 34%

Selling: 66%

Recent trades by BullBearings members
TRADE QTY. PRICE DATE
BUY 1,034 1729p 21/05/13 15:16
SELL 2,606 1729p 21/05/13 15:13
SELL 574 1732p 21/05/13 14:58
SELL 1,159 1716p 21/05/13 11:49
BUY 1,159 1715p 21/05/13 11:38

Popular stocks in GSK's sector

Pharmaceuticals & Biotechnology
EPIC CODE ASK PRICE CHANGE  
ATD 0.60p (-23.08%) TRADE
GMX 1.00p (+46.67%) TRADE
CAT 0.94p (-4.19%) TRADE
ABH 0.06p (-9.09%) TRADE
OXB 2.45p (+1.08%) TRADE
AKT 0.47p (-6.67%) TRADE
ASM 1.77p (-2.30%) TRADE
SHP 2,129.00p (+2.01%) TRADE
HIK 989.00p (+1.28%) TRADE
AZN 3,388.50p (-0.06%) TRADE
CRX 4.50p (+3.03%) TRADE

News & Reports referencing GSK

Glaxo hit by US regulatory delay

GlaxoSmithKline has been hit by a delay to one of the six key drugs on which it was awaiting regulatory decisions this year.

3 weeks ago

Tuesday broker round-up UPDATE

Aberdeeen Asset Management: Morgan Stanley raises target price from 478p to 548p retaining an overweight rating. Bank of America ups target price from 455p to 475p and leaves its neutral rating unchanged. JP Morgan increases target price from 532p to 573p and maintains an overweight rating. Citigroup ups target price from 455p to 470p, while its neutral rating remains unchanged. UBS moves target price from 500p to 520p and retains a buy recommendation. Jefferies revises target price from 420p to 475p and keeps a hold recommendation.

3 weeks ago

GlaxoSmithKline submits application for COPD drug in EU

GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).

4 weeks ago

GSK advances on plans to sell Lucozade and Ribena brands, Q1 results disappoint

FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.

4 weeks ago

Monday broker round-up UPDATE

Admiral Group: Deutsche Bank takes target price from 1140p to 1300p retaining a hold recommendation.

4 weeks ago

Traders' views

Are the Equity markets too confident to ignore geo-political risk and war?

By Ronnie Chopra

The markets seem to be extending their highs in recent days with no concern about the continuing threat of war in the Middle East.

This morning, news that Israeli and Syrian forces have exchanged fire across the ceasefire line in the occupied Golan Heights was largely ignored by the financial markets. 

Sharp fall in silver today – fallen to levels not seen since September 2010

By Ronnie Chopra

This morning silver fell to levels not seen since September 2010 as commodity prices slumped overnight in Asia and this extended in early London trading. Although here is plenty of physical buying from China, India and the Middle East – there is heavy computer ETF selling.

A strong dollar and outperforming equity markets have shifted investor’s attention to more risky assets with silver suffering.

Has the dollar rallied too far, too quickly?

By Ishaq Siddiqi

Despite general US data thus far this week coming in a little softer, the dollar retains a bid tone, as US risk markets keep on posting new highs despite much speculation on whether USD may have rallied a little too far, too quickly.

Today we await CPI numbers and US data including housing, jobless claims and the Philly Fed.)

Will the yen fall again?

By Zoe Fiddes

The depreciation of the Japanese yen has been an ongoing process for many months now, and recent developments have contributed to its continued decline. However, upcoming data might change the direction upwards.

Japan’s currency is once more weakening compared to the US dollar. 

Bad news baked into the mining sector

By Brenda Kelly

Despite the fact that it’s only mid- May, the FTSE100 looks set to record a new high for the 12th consecutive month.

Compared to the likes of the Dow, the Dax and the S&P500, the FTSE being quite heavily weighted with the financial and mining sector has dragged itsheels in re-acquiring a record high level. Perhaps it’s the mining sector that is serving as a drag which since February has seen a total decline of almost 25%.

Trading Videos

ETX Capital Daily Market Bite, 21.05.13: European Markets Choppy On Fedspeak; Rand Hit

Morning Traders' notes

Vodafone Posted its largest ever quarterly fall in key organic service revenue

Daily global markets overview with the overnight activity and what can be expected in the markets today. Information straight from the traders’ desks. Insights on commodities, equities, stocks and forex currencies.

Please select game...

CLOSE

Which trading game would you like to trade with ?